Andrew Schiermeier
Chief Executive Officer chez AvenCell Therapeutics, Inc.
Profil
Andrew D. Schiermeier est membre du conseil d'administration de Kynan Pharmaceuticals et directeur de l'exploitation d'Intellia Therapeutics, Inc. Dans sa carrière antérieure, il a occupé le poste de Chief Operating Officer chez Aura Biosciences, Inc. et de Senior CP & Head-Oncology Business chez Merck KGaA. Il a obtenu un MBA du Collège des Ingénieurs, un doctorat de l'Université de Harvard et un diplôme d'études supérieures de l'Université de Stanford.
Postes actifs de Andrew Schiermeier
| Sociétés | Poste | Début |
|---|---|---|
| Kynan Pharmaceuticals | Director/Board Member | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Chief Executive Officer | 01/08/2021 |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Director/Board Member | - |
Anciens postes connus de Andrew Schiermeier
| Sociétés | Poste | Fin |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Operating Officer | 21/06/2021 |
| MERCK KGAA | Corporate Officer/Principal | 01/01/2016 |
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 01/05/2013 |
Formation de Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
